Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 8/2022

15-02-2022 | Astrocytoma | Head and Neck

Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis

Authors: Ziqin Han, Qiuying Chen, Lu Zhang, Xiaokai Mo, Jingjing You, Luyan Chen, Jin Fang, Fei Wang, Zhe Jin, Shuixing Zhang, Bin Zhang

Published in: European Radiology | Issue 8/2022

Login to get access

Abstract

Objectives

To reveal a radiogenomic correlation between the presence of the T2-fluid-attenuated inversion recovery resection (T2-FLAIR) mismatch sign on MR images and isocitrate dehydrogenase (IDH) mutation status in adult patients with lower-grade gliomas (LGGs).

Methods

A web-based systemic search for eligible literature up to April 13, 2021, was conducted on PubMed, Embase, and the Cochrane Library databases by two independent reviewers. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We included studies evaluating the accuracy of the T2-FLAIR mismatch sign in diagnosing the IDH mutation in adult patients with LGGs. The T2-FLAIR mismatch sign was defined as a T2-hyperintense lesion that is hypointense on FLAIR except for a hyperintense rim.

Results

Fourteen studies (n = 1986) were finally identified. The mean age of patients in the included studies ranged from 38.5 to 56 years. The pooled area under the curve (AUC), sensitivity, and specificity were obtained for each molecular profile: IDHmut-Codel: 0.46 (95% confidence interval [CI]: 0.42–0.50), 1% (95%CI: 0–7%), and 69% (95%CI: 62–75%), respectively; IDHmut-Noncodel: 0.75 (95%CI: 0.71–0.79), 42% (95%CI: 34–50%), and 99% (95%CI: 96–100%), respectively; IDH-Mutation regardless of 1p/19q codeletion status: 0.77 (95%CI: 0.73–0.80), 29% (95%CI: 21–40%), and 99% (95%CI: 92–100%), respectively.

Conclusions

The T2-FLAIR mismatch sign was an insensitive but highly specific marker for IDHmut-Noncodel and IDH-Mutation LGGs, whereas it was not a useful marker for IDHmut-Codel LGGs. The findings might identify the T2-FLAIR mismatch sign as a non-invasive imaging biomarker for the selection of patients with IDH-mutant LGGs.

Key Points

• The T2-FLAIR mismatch sign was not a sensitive sign for IDH mutation in LGGs.
• The T2-FLAIR mismatch sign was related to IDHmut-Noncodel with a specificity of 99%.
• The pooled specificity (69%) of the T2-FLAIR mismatch sign for IDHmut-Codel was low.
Appendix
Available only for authorised users
Literature
1.
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRef
2.
van den Bent MJ, Smits M, Kros JM, Chang SM (2017) Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol 35:2394–2401CrossRef
3.
Kawaguchi T, Sonoda Y, Shibahara I et al (2016) Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 129:505–514CrossRef
4.
Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343CrossRef
5.
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
6.
Foltyn M, Nieto Taborda KN, Neuberger U et al (2020) T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neurooncol Adv 2:vdaa004
7.
Jain R, Johnson DR, Patel SH et al (2020) “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22:936–943CrossRef
8.
Aliotta E, Dutta SW, Feng X et al (2020) Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign. J Neurooncol 149:325–335CrossRef
9.
Batchala PP, Muttikkal TJE, Donahue JH et al (2019) Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 40:426–432PubMedPubMedCentral
10.
Broen MPG, Smits M, Wijnenga MMJ et al (2018) The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 20:1393–1399CrossRef
11.
Kinoshita M, Arita H, Takahashi M et al (2020) Impact of inversion time for FLAIR acquisition on the T2-FLAIR mismatch detectability for IDH-mutant, non-CODEL astrocytomas. Front Oncol 10:596448CrossRef
12.
Kinoshita M, Uchikoshi M, Sakai M, Kanemura Y, Kishima H, Nakanishi K (2021) T2-FLAIR mismatch sign is caused by long T1 and T2 of IDH-mutant, 1p19q non-codeleted astrocytoma. Magn Reson Med Sci 20:119–123CrossRef
13.
Lasocki A, Gaillard F, Gorelik A, Gonzales M (2018) MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 39:687–692CrossRef
14.
Patel SH, Poisson LM, Brat DJ et al (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA Project. Clin Cancer Res 23:6078–6085CrossRef
15.
Throckmorton P, Graber JJ (2020) T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: variability and evolution. Neurology 95:e1582–e1589CrossRef
16.
Yang X, Lin Y, Xing Z, She D, Su Y, Cao D (2020) Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas. Acta Radiol:284185120973624
17.
Maynard J, Okuchi S, Wastling S et al (2020) World Health Organization Grade II/III glioma molecular status: prediction by MRI morphologic features and apparent diffusion coefficient. Radiology 296:111–121CrossRef
18.
Deguchi S, Oishi T, Mitsuya K et al (2020) Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Sci Rep 10:10113CrossRef
19.
Juratli TA, Tummala SS, Riedl A et al (2019) Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 141:327–335CrossRef
20.
Lee MK, Park JE, Jo Y, Park SY, Kim SJ, Kim HS (2020) Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Eur Radiol 30:844–854CrossRef
21.
Johnson DR, Kaufmann TJ, Patel SH, Chi AS, Snuderl M, Jain R (2019) There is an exception to every rule-T2-FLAIR mismatch sign in gliomas. Neuroradiology 61:225–227CrossRef
22.
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71CrossRef
23.
Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536
24.
Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893CrossRef
25.
Hoaglin DC (2016) Misunderstandings about Q and ‘Cochran’s Q test’ in meta-analysis. Stat Med 35:485–495CrossRef
26.
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRef
27.
Devillé WL, Buntinx F, Bouter LM et al (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9
28.
Hellmich M, Lehmacher W (2005) A ruler for interpreting diagnostic test results. Methods Inf Med 44:124–126
29.
Corell A, Ferreyra Vega S, Hoefling N et al (2020) The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. BMC Cancer 20:450CrossRef
30.
Fujita Y, Nagashima H, Tanaka K et al (2021) The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas. World Neurosurg 149:e253–e260
Metadata
Title
Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis
Authors
Ziqin Han
Qiuying Chen
Lu Zhang
Xiaokai Mo
Jingjing You
Luyan Chen
Jin Fang
Fei Wang
Zhe Jin
Shuixing Zhang
Bin Zhang
Publication date
15-02-2022
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 8/2022
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-022-08607-8

Other articles of this Issue 8/2022

European Radiology 8/2022 Go to the issue

Gastrointestinal

Occurrence of peritoneal carcinomatosis in patients with rectal cancer undergoing staging pelvic MRI: clinical observations

Hepatobiliary-Pancreas

Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors

Gastrointestinal

The application of apparent diffusion coefficients derived from intratumoral and peritumoral zones for assessing pathologic prognostic factors in rectal cancer

Hepatobiliary-Pancreas

Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?

Imaging Informatics and Artificial Intelligence

Diagnostic performance of an algorithm for automated collateral scoring on computed tomography angiography

Oncology

A functional liver imaging score for preoperative prediction of liver failure after hepatocellular carcinoma resection